ASCO 2025

De-escalating therapy - a step forward

TRADE: Abemaciclib in eBC

Intraoperative dose escalation helps to reach targeted…

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

WSG: HER2+ pooled analysis

A new standard for endocrine-resistant HR+ MBC?

SERENA-6 - a challenging strategy?

SG + Pembro in aTNBC: a new standard of care?

New compounds - new approaches: TNBC | HR+ | HER2+

AI and ADCs: Precision diagnostics & safer rechallenge…

Triple therapy 1st line | double therapy 2nd line - new…

Next-gen endocrine therapies and ADCs: Updates from…

Future new SOC for PD-L1-positive mTNBC

Re-exposition and ILD

ABC for metastatic TNBC

New treatment option in first line of metastatic TNBC

New SOC in first-line treatment for primary endocrine…

New AKT/PIK3 Antagonist for treatment of mBC after…

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

Liquid biopsy as a navigator for personalized therapy…

Additional chemo-free option for TNBC

New firstline SOC for HER2+ metastatic BC

T-DXd: Detecting ILD and treat again

Vepdegestrant for treatment of ER+/HER2- aBC

Additional ADC effective for untreated TNBC

ASCENT-04

Final OS-Analysis of INAVO-120 trial

SG + Pembrolizumab might become SOC for PD-L1-positive…

Effective ADC for HER2+ mBC with brain metastases

Sac-TMT for metastatic TNBC

SG + Pembrolizumab podría convertirse en el tratamiento…

Analisi finale della OS dello studio INAVO-120

Nuovo antagonista di AKT/PIK3 per il trattamento della…

Nuova opzione di trattamento in prima linea per il TNBC…

Ipatasertib + Fulvestrant mejora la supervivencia libre…

Un nouveau traitement de première ligne pour le TNBC

Vepdegestrant per il trattamento di ER+/HER2- aBC

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

PARP-inhibitor combinations in advanced prostate cancer

Localized CSPC - innovations

mHSPC - ADT + NHT updates

Adding EZH2 to Enzalutamide to decrease the development…

Rebirth of Rucaparib

Real world data from ironman registry confirms…

Niraparib + Abiraterone Improves Outcomes in…

Stereotactic beam radiation therapy 2.0

New way of treatment for PCa

Immuntherapy - an evolution?

CAN-2409 Offers First New Option in 20 Years

mHSPC - prognostification - indications on integration?

Combination of LU-PSMA and immunotherapy, EVOLUTION…

Personalized In Situ Immunotherapy SYNC-T Shows High…

News of ANZUP trial

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

Sasanlimab + BCG: Practice-Changing Potential for…

Complete but Not Finished: EV+P cCR Data Extend the SOC…

ICI Combos in 1L and Maintenance – Mixed Bags or…

New nectin-4 ADCs are coming

ASCO 2025 - Highlights for Bladder Cancer

Benefit of IO/IO therapy in mUC

Update on EV-PEM in the EV-302 study

The role of sansalimab (+ SG) in BCG-naive and…

CREST Study: Promising Results with PD-1 Inhibitor…

mUC - new approaches?

Response matters in advanced urothelial cancer patients…

Intensive caution of BCG Therapy

NIAGARA study and circulating tumor DNA

New option for high-risk NMIBC

A new prognostic factor in bladder cancer?: The case of…

mUC EVP + subsequent therapies

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου…

HIF alfa sigue siendo una diana interesante en el RCC y…

De nouveaux ADC pour la nectine-4 arrivent

La respuesta es importante en pacientes con cáncer…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

Casdatifan + Cabo – Too Early to Call It a Game…

Who Really Benefits? Pembro’s Solid, Atezo’s Still…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

Nivo + Ipi - Update & Insights

First lession

HIF alpha still an interesting target in RCC and other…

Long-term outcome of Nnivo-Ipi in clear cell RCC

5-Year OS data from the KEYNOTE-564 study

Neoadjuvant Approaches in resectable NSCLC: Insights…

CM-816: The OS results are positive and demonstrate…

Chemoimmunotherapy followed by chemoradiotherapy

Neoadjuvant Alectinib in resectable stage III NSCLC

Neadjuvant targeted therapy

cTDNA in periop chemo-IO strategies

CheckMate 816: Update on OS-benefit

ctDNA stratification

Updates in perioperative strategies in NSCLC

CM-816 : Les résultats de l'OS sont positifs et…

Actualizaciones en estrategias perioperatorias en NSCLC

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

ADC in the 3L beats docetaxel

Have we MET our target?

Does the timing of IO-infusion impact survival?

Is there still a place for HER3-DXd in advanced NSCLC?

KRAS G12C: Can immunotherapy improve patient outcome…

Sevarbertinib – an additional option for HER2 exon 20…

Updates on ADCs in EGFR resistance

Benefit of IO is depending on the time of day of…

Time of day of immunotherapy is important

RELA-104-biomarker-analysis

TROP2 targets – where is first-line development…

HER3-DXd: dissapointing negative trial

HERTHENA-Lung02 unfortunately negative study -…

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

ADC as 3L in EGFR

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

KRAS G12C: Kan immunotherapie alleen het resultaat voor…

HERTHENA-Lung02 étude malheureusement négative -…

Actualizaciones sobre los ADC en la resistencia al EGFR

New maintenance therapy for SCLC

Taralatamb - the new SOC in 2L treatment

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

Tarlatamab - a new SOC in second line

New therapies to improve patient survival

De nouvelles thérapies pour améliorer la survie des…

Exercise - The new old wonderdrug